Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 20, Issue 3, 2009, Pages 158-165

  Ciulla, Thomas A ^a,c   Rosenfeld, Philip J ^b  

^a Midwest Eye Institute   (India)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c MIDWEST EYE INSTITUTE   (United States)

Author keywords

Bevacizumab; Macular degeneration; Neovascularization; Pegaptanib sodium; Ranibizumab

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ATG 003; BEVACIZUMAB; BEVASIRANIB; E 10030; ISOPROTEIN; JSM 6427; MECAMYLAMINE; PEGAPTANIB; RANIBIZUMAB; SIRNA 027; SMALL INTERFERING RNA; SORAFENIB; STRONTIUM 90; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VERTEPORFIN; APTAMER; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HEMORRHAGE; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; GENE SILENCING; HUMAN; INFLAMMATION; INTRAOCULAR PRESSURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETINA TEAR; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STROKE; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; UVEITIS; ANIMAL; DRUG ANTAGONISM; FOOD AND DRUG ADMINISTRATION; RETINA MACULA DEGENERATION; UNITED STATES;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DRUG APPROVAL; HUMANS; MACULAR DEGENERATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65549162660     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32832d25b3     Document Type: Review

References (93)

1. Bird A. Age-related macular disease. Br J Ophthalmol 1996; 80:2-3.
2. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26:2653-2664.
3. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006; 124:726-732.
4. Chakravarthy U, Augood C, Bentham GC, et al. Cigarette smoking and age- related macular degeneration in the EUREYE Study. Ophthalmology 2007; 114:1157-1163.
5. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis 1999; 5:34.
6. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
7. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-985.
8. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309-1312.
9. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
10. Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. CurrTop Microbiol Immunol 1999; 237:41-57.
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
12. Gerhardt H, Ruhrberg C, Abramsson A, et al. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 2004; 231:503-509.
13. Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999; 126:4895-4902.
14. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266:11947-11954.
15. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581 -611.
16. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109:227-241.
17. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5:1806-1814.
18. Zhang HT, Scott PA, Morbidelli L, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000; 83:63-68.
19. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4:1317- 1326.
20. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997; 57:765-772.
21. Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999; 59:4129-4135.
22. Weis S, Shintani S, Weber A, et al. Src blockade stabilizes a flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004; 113:885-894.
23. Gilbert RE, Vranes ?, Berka JL, et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998; 78:1017- 1027.
24. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovasculariz- ing ocular diseases. Lab Invest 1995; 72:638-645.
25. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 1996; 37:1334-1340.
26. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000; 156:697-707.
27. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114:66-71.
28. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120:338-346.
29. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81:154- 162.
30. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37:1929-1934.
31. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44:3186-3193.
32. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisa- tion. Br J Ophthalmol 1996; 80:363-366.
33. Adamis AP, Miller J W, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118:445-450.
34. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487.
35. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006; 244:309-315.
36. Pe'er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105:412- 416.
37. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 2006; 47:329- 335.
38. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006; 15:2955-2961.
39. Lin JM, Wan L, Tsai YY, et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol 2008; 145:1045-1051. This study revealed a VEGF SNP (+936T) that, together with the complement factor polymorphism Y402H, could be a potential predictor of increased risk for developing wet AMD in elderly populations. This study adds to the growing list of risk factors for AMD and strengthens the basis for a potentially more fruitful pharmacogenomic approach to the management ocular diseases.
40. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805- 2816.
41. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age- related macular degeneration. Ophthalmology 2006; 113:1508-1525.
42. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age- related macular degeneration. N Engl J Med 2006; 355:1419-1431.
43. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
44. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:1868-1875.
45. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography- guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143:566-583. OCT can be used to accurately detect the earliest sign of recurrent macular fluid accumulation after cessation of ranibizumab injections. OCT-guided, variable dosing retreatment resulted in visual acuity outcomes similar to the phase III trials using fewer intravitreal injections.
46. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239-248.
47. Ranibizumab (0.3 or 0.5 mg) administered monthly and then quarterly thereafter was well tolerated and provided significant and clinically meaningful visual acuity improvement to patients with all angiographic subtypes of AMD-related CNV. However, the quarterly treatments were associated with a decline from the benefit achieved with monthly therapy.
48. Michels M, Francom S, Wilson L. Systemic safety and risk factors associated with intravitreal ranibizumab in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) [abstract]. In: 26th Annual Meeting of the American Society of Retina Specialists; 11-15 October 2008; Maui, Hawaii. The SAILOR study showed no significant differences in the rates of cardiovascular and nonocular adverse events between patients receiving high-dose (0.5 mg) and low-dose (0.3 mg) ranibizumab. A history of stroke, heart failure, and arterial thromboembolic events was predictive of stroke, regardless of the treatment dose. This may alleviate concerns regarding the low rates of arterial thromboembolic events earlier reported in the MARINA and ANCHOR studies. 48 Kokame G, Francom S, Yee W. Ocular safety of ranibizumab (LUCENTIS) in patients with wet age-related macular degeneration: SAILOR and 3 additional randomized, multicenter trials [abstract]. In: 26th Annual Meeting of the American Society of Retina Specialists; 11-15 October 2008; Maui, Hawaii.
49. Ferrone PJ, Francom S, Tuomi L. Efficacy of ranibizumab (LUCENTIS) in patients with wet age-related macular degeneration: subgroup analysis of SAILOR study cohort 1 [abstract]. In: 26th Annual Meeting of the American Society of Retina Specialists; 11-15 October 2008; Maui, Hawaii.
50. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112:1035-1047.
51. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113:e1-e12.
52. Geitzenauer W, Michels S, Prager F, et al. Early effects of systemic and intravitreal bevacizumab (Avastin) therapy for neovascular age-related macular degeneration [in German]. Klin Monatsbl Augenheilkd 2006; 223:822- 827.
53. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331 -335.
54. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26:495-511.
55. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26:383-390.
56. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26:994-998.
57. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007; 245:215-220.
58. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007; 27:445-450.
59. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27:439-444.
60. Goff MJ, Johnson RN, McDonald HR, et al. Intravitreal bevacizumab for previously treated choroidal neovascular from age-related macular degeneration. Retina 2007; 27:432-438.
61. Madhusudhana KC, Hannan SR, Williams CP, et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 2007; 91:1716-1717.
62. Pedersen R, Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007; 85:526-533.
63. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 2007; 22:82-86.
64. Ghazi NG, Knape RM, Kirk TQ, et al. Intravitreal bevacizumab (Avastin) treatment of retinal angiomatous proliferation. Retina 2008; 28:689- 695.
65. Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007; 85:563- 565.
66. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008; 146:91 -95.
67. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246:81-87.
68. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372e5.
69. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142:1 -9.
70. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose- escalation study. Invest Ophthalmol Vis Sci 2006; 47:4569-4578.
71. Aisenbrey S, Ziemssen F, Volker M, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245:941 -948.
72. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008; 86:482-489.
73. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143:510-512.
74. Giansanti F, Virgili G, Bini A, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007; 17:230-237.
75. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2006; 245:68-73.
76. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125:1357-1361.
77. Azad RV, Khan MA, Chanana B, Azad S. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol 2008; 52:52-56.
78. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145:249-256.
79. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008; 92:356-360.
80. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 2007; 90:1344-1349.
81. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007; 245:1273-1280.
82. Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26:988-993.
83. Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008; 246:17-25.
84. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006; 37:446-454.
85. Diago T, Pulido JS, Molina JR, et al. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 2008; 83:231-234.
86. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9:210-216.
87. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004; 24:132-138.
88. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452:591 -597. siRNAs of at least 21 nucleotides long are effective for treating angiogenic diseases regardless of target specificity via a class effect that may also lead to unanticipated and undesirable vascular or immune effects.
89. Yang Z, Stratton C, Francis PJ, et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2008; 359: 1456-1463.
90. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 2006; 26:602-612.
91. Ergun E, Maar N, Ansari-Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 2006; 142:10-16.
92. Schmidt-Erfurth U, Michels S, Augustin A. Perspectives on verteporfin therapy combined with intravitreal corticosteroids. Arch Ophthalmol 2006; 124:561 - 563.
93. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005; 25:685-690.